Does the media favor MRVI or CAI?

In the previous week, Caris Life Sciences had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Caris Life Sciences and 2 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 0.70 beat Maravai LifeSciences' score of 0.25 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STVN or MRVI?

Maravai LifeSciences has a consensus target price of $6.83, suggesting a potential downside of 1.96%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86 Maravai LifeSciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer STVN or MRVI?

In the previous week, Maravai LifeSciences had 1 more articles in the media than Stevanato Group. MarketBeat recorded 2 mentions for Maravai LifeSciences and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.89 beat Maravai LifeSciences' score of 0.25 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRVI or SHC?

In the previous week, Maravai LifeSciences had 1 more articles in the media than Sotera Health. MarketBeat recorded 2 mentions for Maravai LifeSciences and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.73 beat Maravai LifeSciences' score of 0.25 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sotera Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRVI or ADPT?

In the previous week, Adaptive Biotechnologies had 11 more articles in the media than Maravai LifeSciences. MarketBeat recorded 13 mentions for Adaptive Biotechnologies and 2 mentions for Maravai LifeSciences. Adaptive Biotechnologies' average media sentiment score of 0.45 beat Maravai LifeSciences' score of 0.25 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRVI or ALMR?

In the previous week, Alamar Biosciences had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Maravai LifeSciences. Alamar Biosciences' average media sentiment score of 0.34 beat Maravai LifeSciences' score of 0.25 indicating that Alamar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Maravai LifeSciences (MRVI) Competitors

$6.97 -0.30 (-4.13%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.00 +0.03 (+0.40%)

As of 09/18/2026 07:56 PM Eastern

Compare

MRVI vs. CAI, STVN, SHC, ADPT, and ALMR

Should you buy Maravai LifeSciences stock or one of its competitors? Maravai LifeSciences's main competitors and comparable companies include Caris Life Sciences (CAI), Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), and Alamar Biosciences (ALMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Maravai LifeSciences compare to Caris Life Sciences?

Maravai LifeSciences (NASDAQ:MRVI) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Caris Life Sciences had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Caris Life Sciences and 2 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 0.70 beat Maravai LifeSciences' score of 0.25 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a net margin of 10.62% compared to Maravai LifeSciences' net margin of -37.07%. Caris Life Sciences' return on equity of 18.77% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Caris Life Sciences	10.62%	18.77%	9.34%

Caris Life Sciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A
Caris Life Sciences	$812.03M	10.43	-$68.09M	$0.36	83.28

Maravai LifeSciences presently has a consensus price target of $6.83, indicating a potential downside of 1.96%. Caris Life Sciences has a consensus price target of $26.50, indicating a potential downside of 11.61%. Given Maravai LifeSciences' higher probable upside, research analysts plainly believe Maravai LifeSciences is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Maravai LifeSciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Summary

Caris Life Sciences beats Maravai LifeSciences on 14 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Stevanato Group has a net margin of 10.99% compared to Maravai LifeSciences' net margin of -37.07%. Stevanato Group's return on equity of 10.43% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

50.3% of Maravai LifeSciences shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Stevanato Group has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.89	€158.21M	€0.56	38.68
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A

In the previous week, Maravai LifeSciences had 1 more articles in the media than Stevanato Group. MarketBeat recorded 2 mentions for Maravai LifeSciences and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.89 beat Maravai LifeSciences' score of 0.25 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maravai LifeSciences has a consensus target price of $6.83, suggesting a potential downside of 1.96%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Stevanato Group has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

Summary

Stevanato Group beats Maravai LifeSciences on 11 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Sotera Health?

Maravai LifeSciences (NASDAQ:MRVI) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Sotera Health has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A
Sotera Health	$1.16B	4.59	$77.94M	$0.57	32.86

Maravai LifeSciences has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Sotera Health has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Sotera Health has a net margin of 13.44% compared to Maravai LifeSciences' net margin of -37.07%. Sotera Health's return on equity of 40.12% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Sotera Health	13.44%	40.12%	7.55%

Maravai LifeSciences currently has a consensus target price of $6.83, indicating a potential downside of 1.96%. Sotera Health has a consensus target price of $21.50, indicating a potential upside of 14.79%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts plainly believe Sotera Health is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Maravai LifeSciences had 1 more articles in the media than Sotera Health. MarketBeat recorded 2 mentions for Maravai LifeSciences and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.73 beat Maravai LifeSciences' score of 0.25 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sotera Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 91.0% of Sotera Health shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 15.4% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sotera Health beats Maravai LifeSciences on 14 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Maravai LifeSciences (NASDAQ:MRVI) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Maravai LifeSciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

Adaptive Biotechnologies has a net margin of -20.73% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.70% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Maravai LifeSciences currently has a consensus target price of $6.83, indicating a potential downside of 1.96%. Adaptive Biotechnologies has a consensus target price of $24.42, indicating a potential downside of 14.66%. Given Maravai LifeSciences' higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Adaptive Biotechnologies has higher revenue and earnings than Maravai LifeSciences. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A
Adaptive Biotechnologies	$276.98M	16.49	-$59.50M	-$0.41	N/A

In the previous week, Adaptive Biotechnologies had 11 more articles in the media than Maravai LifeSciences. MarketBeat recorded 13 mentions for Adaptive Biotechnologies and 2 mentions for Maravai LifeSciences. Adaptive Biotechnologies' average media sentiment score of 0.45 beat Maravai LifeSciences' score of 0.25 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Adaptive Biotechnologies beats Maravai LifeSciences on 12 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Alamar Biosciences?

Maravai LifeSciences (NASDAQ:MRVI) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Maravai LifeSciences currently has a consensus target price of $6.83, indicating a potential downside of 1.96%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential downside of 8.75%. Given Maravai LifeSciences' higher possible upside, equities research analysts clearly believe Maravai LifeSciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alamar Biosciences has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -37.07%. Alamar Biosciences' return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Alamar Biosciences	N/A	N/A	N/A

Alamar Biosciences has lower revenue, but higher earnings than Maravai LifeSciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A
Alamar Biosciences	$74.21M	32.59	-$29.82M	-$1.96	N/A

In the previous week, Alamar Biosciences had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Maravai LifeSciences. Alamar Biosciences' average media sentiment score of 0.34 beat Maravai LifeSciences' score of 0.25 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alamar Biosciences beats Maravai LifeSciences on 9 of the 15 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.81B	$10.40B	$7.24B	$13.19B
Dividend Yield	N/A	1.46%	2.57%	12.81%
P/E Ratio	-13.40	70.70	275.49	25.40
Price / Sales	9.74	108.53	646.01	89.45
Price / Cash	16.65	27.47	76.25	51.42
Price / Book	4.77	5.70	10.46	6.33
Net Income	-$130.77M	$56.67B	$3.49B	$358.33M
7 Day Performance	6.74%	4.59%	0.59%	1.12%
1 Month Performance	-15.92%	0.07%	-1.74%	-2.39%
1 Year Performance	158.15%	27.93%	18.13%	5.35%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.1705 of 5 stars	$6.97 -4.1%	$6.83 -2.0%	+158.1%	$1.81B	$185.74M	N/A	415	News Coverage
CAI Caris Life Sciences	3.1998 of 5 stars	$25.37 +1.2%	$26.33 +3.8%	N/A	$7.18B	$812.03M	70.56	1,846	Analyst Upgrade Insider Trade Gap Down
STVN Stevanato Group	2.7838 of 5 stars	€20.34 -0.9%	N/A	-19.4%	€6.16B	€1.34B	36.32	6,010
SHC Sotera Health	3.9619 of 5 stars	$18.69 -1.1%	$21.50 +15.1%	+19.8%	$5.33B	$1.16B	32.78	3,000	Positive News
ADPT Adaptive Biotechnologies	1.8901 of 5 stars	$24.39 +0.5%	$24.42 +0.1%	+114.1%	$3.89B	$276.98M	N/A	790	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. CAI, STVN, SHC, ADPT, and ALMR

How does Maravai LifeSciences compare to Caris Life Sciences?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Summary

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Summary

How does Maravai LifeSciences compare to Alamar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. CAI, STVN, SHC, ADPT, and ALMR

How does Maravai LifeSciences compare to Caris Life Sciences?

Do institutionals and insiders believe in MRVI or CAI?

Does the media favor MRVI or CAI?

Is MRVI or CAI more profitable?

Which has higher valuation & earnings, MRVI or CAI?

Do analysts prefer MRVI or CAI?

Which has more risk & volatility, MRVI or CAI?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Is STVN or MRVI more profitable?

Do insiders and institutionals have more ownership in STVN or MRVI?

Which has better valuation and earnings, STVN or MRVI?

Does the media prefer STVN or MRVI?

Do analysts prefer STVN or MRVI?

Which has more volatility & risk, STVN or MRVI?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Which has preferable valuation and earnings, MRVI or SHC?

Which has more volatility and risk, MRVI or SHC?

Is MRVI or SHC more profitable?

Do analysts prefer MRVI or SHC?

Does the media prefer MRVI or SHC?

Do insiders & institutionals hold more shares of MRVI or SHC?

Summary

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Which has more risk and volatility, MRVI or ADPT?

Is MRVI or ADPT more profitable?

Do analysts rate MRVI or ADPT?

Which has better valuation & earnings, MRVI or ADPT?

Does the media favor MRVI or ADPT?

Do institutionals & insiders hold more shares of MRVI or ADPT?

Summary

How does Maravai LifeSciences compare to Alamar Biosciences?

Do insiders and institutionals believe in MRVI or ALMR?

Do analysts rate MRVI or ALMR?

Is MRVI or ALMR more profitable?

Which has preferable valuation and earnings, MRVI or ALMR?

Does the media prefer MRVI or ALMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools